Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 were associated with a lower rate of serious infections among older adults with psoriatic disease, a Canadian cohort study showed.

Discover 5 insights about psoriatic arthritis from rheumatology experts, including pain management strategies, treatment ...

1 The prospective, multicenter study is published in the Journal of Psoriasis and Psoriatic Arthritis. “Female sex was associated with shorter overall drug survival for all biologics combined ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its monoclonal antibody Tremfya (guselkumab) for active psoriatic arthritis (PsA).

Factors associated with multi-b/tsDMARD failure among patients with PsA included female sex, obesity, depression, axial disease, and increased disease activity.

Stelara was first approved for psoriasis 10 years ago, and follow-up indications in psoriatic arthritis and Crohn ... year despite approvals for new biologics drugs in its main therapeutic ...

And people with extensive arthritis affecting five or more joints were less likely to be prescribed antirheumatic drugs if they had psoriatic arthritis compared to rheumatoid arthritis ...

Rheumatoid arthritis (RA) patients in Denmark with a history of solid tumor cancers, now in remission, faced no greater likelihood of cancer relapse when they were treated with biologic agents, ...